Average Insider

Where insiders trade, we follow

Insider Buy/Sell Details for the Healthcare Sector — April 2026

Extreme outlier transactions (>3σ) are excluded.Show All Data
Ratio0.1:1
Daily Buy & Sell Volume

Immunome Inc. (IMNM)

Rosett Max — Chief Financial Officer
Apr 2, 2026
Sale
Shares
1,344
Price
$22.48
Total Value
$30.21K
Shares Held After
54,037
% of Holdings
2.4%

Immunome Inc. (IMNM)

Rosett Max — Chief Financial Officer
Apr 2, 2026
Sale
Shares
63,656
Price
$21.91
Total Value
$1.39M
Shares Held After
55,381
% of Holdings
53.5%

Immunome Inc. (IMNM)

Higgins Jack — Chief Scientific Officer
Apr 2, 2026
Sale
Shares
9,438
Price
$21.64
Total Value
$204.24K
Shares Held After
22,000
% of Holdings
30.0%

Teladoc Health, Inc. (TDOC)

Catapano Joseph Ronald — Chief Accounting Officer
Apr 2, 2026
Sale
Shares
675
Price
$5.11
Total Value
$3.45K
Shares Held After
10,249
% of Holdings
6.2%
Apr 2, 2026
Sale
Shares
26,858
Price
$3.48
Total Value
$93.47K
Shares Held After
793,549
% of Holdings
3.3%

Zai Lab Ltd (ZLAB)

Du Ying — Director
Apr 2, 2026
Sale
Shares
5,576
Price
$20.39
Total Value
$113.69K
Shares Held After
1,125,279
% of Holdings
0.5%

Zai Lab Ltd (ZLAB)

Chen Yajing — Chief Financial Officer
Apr 2, 2026
Sale
Shares
5,199
Price
$20.39
Total Value
$106.01K
Shares Held After
32,558
% of Holdings
13.8%

Zai Lab Ltd (ZLAB)

Smiley Joshua L — President and Chief Operating Officer
Apr 2, 2026
Sale
Shares
9,614
Price
$20.39
Total Value
$196.03K
Shares Held After
120,619
% of Holdings
7.4%

Zai Lab Ltd (ZLAB)

Amado Rafael — President, Head of Global Oncology Research and Development
Apr 2, 2026
Sale
Shares
9,910
Price
$20.39
Total Value
$202.06K
Shares Held After
59,761
% of Holdings
14.2%
Apr 2, 2026
Sale
Shares
11,511
Price
$3.87
Total Value
$44.55K
Shares Held After
472,549
% of Holdings
2.4%

Zai Lab Ltd (ZLAB)

Edmondson Frazor Titus III — Chief Legal Officer
Apr 2, 2026
Sale
Shares
4,194
Price
$20.39
Total Value
$85.52K
Shares Held After
24,590
% of Holdings
14.6%

SI-BONE, Inc. (SIBN)

PISETSKY MICHAEL A. — SVP, Ops & Adm/Chief Legal Ofr
Apr 2, 2026
Sale
Shares
34
Price
$12.61
Total Value
$428.74
Shares Held After
282,840
% of Holdings
0.0%

SI-BONE, Inc. (SIBN)

PISETSKY MICHAEL A. — SVP, Ops & Adm/Chief Legal Ofr
Apr 2, 2026
Sale
Shares
1,301
Price
$12.86
Total Value
$16.74K
Shares Held After
282,874
% of Holdings
0.5%

SI-BONE, Inc. (SIBN)

Maheshwari Anshul — Chief Financial Officer
Apr 2, 2026
Sale
Shares
1,560
Price
$12.81
Total Value
$19.99K
Shares Held After
263,148
% of Holdings
0.6%

SI-BONE, Inc. (SIBN)

Maheshwari Anshul — Chief Financial Officer
Apr 2, 2026
Sale
Shares
1,758
Price
$12.92
Total Value
$22.72K
Shares Held After
264,708
% of Holdings
0.7%

Sight Sciences, Inc. (SGHT)

Bauerlein Alison — Chief Operating Officer
Apr 2, 2026
Sale
Shares
25,874
Price
$3.48
Total Value
$90.04K
Shares Held After
701,621
% of Holdings
3.6%
Apr 2, 2026
Sale
Shares
8,168
Price
$3.48
Total Value
$28.42K
Shares Held After
1,990,290
% of Holdings
0.4%
Apr 2, 2026
Sale
Shares
7,529
Price
$32.00
Total Value
$240.93K
Shares Held After
0
% of Holdings
100.0%
Apr 2, 2026
Purchase
Shares
713,800
Price
$2.10
Total Value
$1.50M
Shares Held After
3,288,539
% of Holdings
21.7%

Immunovant, Inc. (IMVT)

Venker Eric — Director
Apr 2, 2026
Sale
Shares
1,409
Price
$24.60
Total Value
$34.66K
Shares Held After
19,561
% of Holdings
6.7%

Immunovant, Inc. (IMVT)

Venker Eric — Director
Apr 2, 2026
Sale
Shares
12,820
Price
$24.04
Total Value
$308.19K
Shares Held After
20,970
% of Holdings
37.9%

Avalo Therapeutics, Inc. (AVTX)

Sullivan Christopher Ryan — Chief Financial Officer
Apr 2, 2026
Sale
Shares
1,780
Price
$17.57
Total Value
$31.27K
Shares Held After
17,338
% of Holdings
9.3%

Avalo Therapeutics, Inc. (AVTX)

Sullivan Christopher Ryan — Chief Financial Officer
Apr 2, 2026
Sale
Shares
6,200
Price
$17.02
Total Value
$105.55K
Shares Held After
19,118
% of Holdings
24.5%
Apr 2, 2026
Sale
Shares
2,529,491
Price
$3.28
Total Value
$8.29M
Shares Held After
10,265,297
% of Holdings
19.8%
Apr 2, 2026
Sale
Shares
2,634,506
Price
$3.28
Total Value
$8.64M
Shares Held After
12,666,731
% of Holdings
17.2%

Kodiak Sciences Inc. (KOD)

BORGESON JOHN A. — Chief Financial Officer
Apr 2, 2026
Sale
Shares
600
Price
$41.77
Total Value
$25.06K
Shares Held After
183,316
% of Holdings
0.3%

Kodiak Sciences Inc. (KOD)

BORGESON JOHN A. — Chief Financial Officer
Apr 2, 2026
Sale
Shares
4,231
Price
$40.88
Total Value
$172.96K
Shares Held After
183,916
% of Holdings
2.2%

Kodiak Sciences Inc. (KOD)

BORGESON JOHN A. — Chief Financial Officer
Apr 2, 2026
Sale
Shares
12,477
Price
$40.29
Total Value
$502.70K
Shares Held After
188,147
% of Holdings
6.2%

Kodiak Sciences Inc. (KOD)

BORGESON JOHN A. — Chief Financial Officer
Apr 2, 2026
Sale
Shares
12,692
Price
$39.14
Total Value
$496.76K
Shares Held After
200,624
% of Holdings
5.9%

UNITED THERAPEUTICS Corp (UTHR)

MAHON PAUL A — EVP & GENERAL COUNSEL
Apr 2, 2026
Sale
Shares
200
Price
$571.61
Total Value
$114.32K
Shares Held After
45,172
% of Holdings
0.4%

UNITED THERAPEUTICS Corp (UTHR)

MAHON PAUL A — EVP & GENERAL COUNSEL
Apr 2, 2026
Sale
Shares
710
Price
$569.61
Total Value
$404.42K
Shares Held After
45,372
% of Holdings
1.5%

UNITED THERAPEUTICS Corp (UTHR)

MAHON PAUL A — EVP & GENERAL COUNSEL
Apr 2, 2026
Sale
Shares
690
Price
$568.79
Total Value
$392.47K
Shares Held After
46,082
% of Holdings
1.5%

UNITED THERAPEUTICS Corp (UTHR)

MAHON PAUL A — EVP & GENERAL COUNSEL
Apr 2, 2026
Sale
Shares
1,403
Price
$567.55
Total Value
$796.27K
Shares Held After
46,772
% of Holdings
2.9%

UNITED THERAPEUTICS Corp (UTHR)

MAHON PAUL A — EVP & GENERAL COUNSEL
Apr 2, 2026
Sale
Shares
1,629
Price
$566.66
Total Value
$923.10K
Shares Held After
48,175
% of Holdings
3.3%

UNITED THERAPEUTICS Corp (UTHR)

MAHON PAUL A — EVP & GENERAL COUNSEL
Apr 2, 2026
Sale
Shares
543
Price
$565.66
Total Value
$307.15K
Shares Held After
49,804
% of Holdings
1.1%

UNITED THERAPEUTICS Corp (UTHR)

MAHON PAUL A — EVP & GENERAL COUNSEL
Apr 2, 2026
Sale
Shares
1,115
Price
$564.55
Total Value
$629.48K
Shares Held After
50,347
% of Holdings
2.2%

UNITED THERAPEUTICS Corp (UTHR)

MAHON PAUL A — EVP & GENERAL COUNSEL
Apr 2, 2026
Sale
Shares
371
Price
$563.58
Total Value
$209.09K
Shares Held After
51,462
% of Holdings
0.7%

UNITED THERAPEUTICS Corp (UTHR)

MAHON PAUL A — EVP & GENERAL COUNSEL
Apr 2, 2026
Sale
Shares
774
Price
$562.34
Total Value
$435.25K
Shares Held After
51,833
% of Holdings
1.5%

UNITED THERAPEUTICS Corp (UTHR)

MAHON PAUL A — EVP & GENERAL COUNSEL
Apr 2, 2026
Sale
Shares
351
Price
$561.69
Total Value
$197.15K
Shares Held After
52,607
% of Holdings
0.7%

UNITED THERAPEUTICS Corp (UTHR)

MAHON PAUL A — EVP & GENERAL COUNSEL
Apr 2, 2026
Sale
Shares
514
Price
$560.30
Total Value
$287.99K
Shares Held After
52,958
% of Holdings
1.0%

IONIS PHARMACEUTICALS INC (IONS)

Devers Shannon L. — EVP, Chief Human Resources Ofc
Apr 2, 2026
Sale
Shares
6,193
Price
$74.05
Total Value
$458.61K
Shares Held After
16,348
% of Holdings
27.5%
Apr 2, 2026
Sale
Shares
19,060
Price
$14.60
Total Value
$278.28K
Shares Held After
447,202
% of Holdings
4.1%
Apr 2, 2026
Purchase
Shares
106,236
Price
$8.31
Total Value
$882.41K
Shares Held After
8,924,329
% of Holdings
1.2%

Nurix Therapeutics, Inc. (NRIX)

Ring Christine — Chief Legal Officer
Apr 2, 2026
Sale
Shares
8,148
Price
$15.24
Total Value
$124.15K
Shares Held After
26,453
% of Holdings
23.5%

Edwards Lifesciences Corp (EW)

BOBO DONALD E JR — CVP,Strategy/Corp Development
Apr 2, 2026
Sale
Shares
18,004
Price
$80.05
Total Value
$1.44M
Shares Held After
21,266
% of Holdings
45.8%

Edwards Lifesciences Corp (EW)

BOBO DONALD E JR — CVP,Strategy/Corp Development
Apr 2, 2026
Sale
Shares
4,676
Price
$80.59
Total Value
$376.85K
Shares Held After
39,270
% of Holdings
10.6%
Apr 2, 2026
Sale
Shares
4,200
Price
$64.89
Total Value
$272.53K
Shares Held After
767,780
% of Holdings
0.5%
Apr 2, 2026
Sale
Shares
15,800
Price
$64.06
Total Value
$1.01M
Shares Held After
771,980
% of Holdings
2.0%

Lipocine Inc. (LPCN)

Patel Mahesh V. — Director
Apr 2, 2026
Purchase
Shares
25,000
Price
$2.02
Total Value
$50.50K
Shares Held After
135,679
% of Holdings
18.4%

Spyre Therapeutics, Inc. (SYRE)

Burrows Scott L — Chief Financial Officer
Apr 1, 2026
Sale
Shares
1,300
Price
$49.98
Total Value
$64.97K
Shares Held After
97,994
% of Holdings
1.3%
Version: v26.3.33